Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

HK40110065BActive Publication Date: 2026-07-10UNIV AVEIRO +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
UNIV AVEIRO
Filing Date
2024-10-23
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Existing NADPH oxidase inhibitors have low solubility in aqueous solutions, resulting in insufficient bioavailability and therapeutic potential. They cannot effectively target Nox1 and Nox4, limiting their application in neurodegenerative diseases such as Parkinson's disease.

Method used

The specific NADPH oxidase inhibitor 3-cyclohexyl-5-(2,4-dihydroxybenzylmethyl)-1-methyl-2-thiohydantoin was reformulated into an ionic liquid-based choline salt ([Chol]2[N1(4)inh]+N1(4)inh) to improve its solubility and bioavailability in aqueous solution and to bypass the blood-brain barrier via intranasal delivery.

Benefits of technology

It improves the solubility and bioavailability of inhibitors, reduces neurotoxicity, and shows high neuroprotective potential, effectively slowing the progression of Parkinson's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000030_0000
    Figure 00000030_0000
  • Figure 00000031_0000
    Figure 00000031_0000
  • Figure 00000032_0000
    Figure 00000032_0000
Patent Text Reader

Abstract

The present disclosure relates to an ionic liquid (IL)-based formulation for the treatment, therapy or prevention of a nervous system disease, in particular Parkinson's disease, said formulation comprising an inhibitor, in particular a specific inhibitor, of NADPH oxidase (Nox), preferably isoforms 1 and 4, 3-cyclohexyl-5-(2,4-dihydroxybenzylidene)-1-methyl-2-thiohydantoin.
Need to check novelty before this filing date? Find Prior Art